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ABSTRACT
Introduction: Acute bacterial skin and skin
structure infections (ABSSSI) are an increasing
cause of admission in the self-pay population.
We previously reported that patients with
ABSSSI discharged to receive dalbavancin
showed a decreased length of stay (LOS) and
total direct costs without increasing 30-day
readmission rate. For patients who are finan-
cially eligible, a dalbavancin vial replacement
program can offset costs. The objective of this
study was to determine cost differences in
treating ABSSSI in self-pay inpatients discharged
to receive dalbavancin compared to standard of
care (SOC).
Methods: This retrospective cohort within a
community health system compared self-pay
adult inpatients with ABSSSI from February 3,
2016 to August 5, 2019 discharged to receive
dalbavancin at an outpatient infusion center
with SOC intravenous antibiotics. Patients were
included with cellulitis, abscess, or postopera-
tive wound infections diagnoses on the basis of
International Classification of Disease, Tenth
Revision (ICD-10) codes. Excluded populations
were patients without dalbavancin vial
replacement performed, pregnant, infections
caused exclusively by gram-negative bacteria or
fungi, or ICD-10 codes not consistent with
ABSSSI. The primary outcome was direct cost of
hospital stay. Secondary outcomes included
length of stay (LOS), 30-day readmission rates,
adverse events (AE), and indirect hospital costs.
On the basis of previous studies, a one-sided
Student’s t test was performed on financial data.
Results: Twelve dalbavancin and 263 SOC
patients met inclusion criteria. Direct cost
($2758 vs $4010, p = 0.105) and indirect hos-
pital cost ($2913 vs $3646 , p = 0.162) per
patient were less in the dalbavancin group.
There was no significant difference between
median LOS (4 vs 4, p = 0.888), AE (0% vs
14.8%), and 30-day readmission rates for dal-
bavancin vs SOC group (8.3% vs 7.2%,
p = 0.604).
Conclusion: Self-pay patients with ABSSSI dis-
charged to receive dalbavancin with vial
replacement resulted in decreased direct and
indirect costs per patient with similar 30-day
readmission rates, AE, and LOS. More studies
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to determine ultimate benefit.
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Key Summary Points
Acute bacterial skin and skin structure
infections (ABSSSI) are an increasing cause
of admission in the self-pay population.
Dalbavancin, a novel lipoglycopeptide,
has been shown to decrease length of stay
(LOS) and total direct costs without
increasing 30-day readmission rate.
The objective of this study was to examine
the potential cost savings in treating self-
pay inpatients with ABSSSI discharged to
receive dalbavancin compared to standard
of care (SOC).
Self-pay patients with ABSSSI discharged
to receive dalbavancin with vial
replacement resulted in decreased direct
and indirect costs per patient with similar
30-day readmission rates, AE, and LOS.
More studies targeted toward this
population are warranted to determine
ultimate benefit.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.12771209.
INTRODUCTION
Acute bacterial skin and skin structure infec-
tions (ABSSSI) are defined by the US Food and
Drug Administration (FDA) as a bacterial infec-
tion of the skin with erythema, tenderness,
warmth, or swelling. The lesion size should be
at least 75 cm2, measured by the area of redness,
edema, or induration. These include cellulitis/
erysipelas, wound infections, and major cuta-
neous abscesses. The most common causative
pathogens are Streptococcus pyogenes and Sta-
phylococcus aureus, including methicillin-resis-
tant S. aureus (MRSA) [1, 2]. ABSSSI are common
reasons for presenting to doctor’s offices and
hospitals. While many low-risk patients who
present to the emergency department are able
to be treated as outpatients, hospital admissions
for ABSSSI continue to rise [3–5].
According to the US Census Bureau, in 2018,
27.5 million (8.5%) people were classified as
uninsured (i.e., self-pay), which was an increase
of 0.5% from 2017 [6]. Of these, the majority
(13.8%) are classified as having the lowest
income (less than $25,000 US dollars household
income) [6, 7]. While this is but a fraction of the
total US population, hospitals risk having to
cover uncompensated healthcare costs on their
own with this patient population. According to
the American Hospital Association, in 2017,
community hospitals provided $38.4 billion in
uncompensated care cost [8]. Understanding
the financial impact of treating this patient
population could improve financial decision-
making.
ABSSSI has been increasing as a cause for
admissions in the self-pay patient population
[9]. In a previous study conducted at our insti-
tution, dalbavancin resulted in decreased LOS
and 30-day readmission rate compared to
national data for patients with ABSSSI. While
this ultimately led to a reduction in cost for the
healthcare system, it included different patient
socioeconomic statuses [10]. Dalbavancin, a
long-acting lipoglycopeptide, is FDA indicated
to treat adult patients with ABSSSI caused by
susceptible isolates of the following gram-posi-
tive microorganisms: S. aureus (including
MRSA), S. pyogenes, Streptococcus agalactiae, and
the Streptococcus anginosus group. It is a 30-min,
single intravenous (IV) infusion that is an
alternative for the treatment of ABSSSI [11, 12].
Previous studies with dalbavancin have shown
reductions in length of stay (LOS) and inpatient
cost for ABSSSI [13–18]. Additionally, the man-
ufacturer of dalbavancin has a patient assistance
1044 Infect Dis Ther (2020) 9:1043–1053
program that provides the drug at no cost
through vial replacement for patients who are
financially eligible (including patients who are
uninsured or underinsured and unable to afford
the cost of therapy) [19, 20]. After reviewing the
current available literature, there are no current
data on the self-pay population who receive
dalbavancin outpatient compared to traditional
inpatient treatment of ABSSSI. The aim of this
study was to determine if there is a cost differ-
ence in treatment of ABSSSI in self-pay patients
discharged and treated as an outpatient with
dalbavancin compared to traditional inpatient
IV antibiotic treatment, standard of care (SOC).
METHODS
This study was conducted under institutional
review board approval from St. Joseph’s/Candler
Health System which includes two hospitals
and one outpatient infusion center included in
the study. In addition, this study adheres to the
declaration of Helsinki of 1964 and its later
amendments.
The current process for receipt of dalba-
vancin began in February of 2016. A retrospec-
tive cohort was compiled via a computer-
generated report from February 3, 2016 to
August 5, 2019. Patients admitted with an
ABSSSI were collected into two groups: one that
received dalbavancin after discharge and a SOC
group with no intervention for dalbavancin. In
the dalbavancin group, patients were selected
on the basis of evaluation from the infectious
diseases pharmacist (ID PharmD) or the physi-
cian. This evaluation targets specific patient
populations that may benefit from dalbavancin
therapy (e.g., limited comorbidities, failed out-
patient antibiotics, IV drug users (IVDU)). All
patients that were admitted for IV antibiotic
therapy were analyzed using systemic inflam-
matory response syndrome criteria (tempera-
ture[ 38 C or\36 C, heart rate[ 90 beats/
min, respiratory rate[ 20 breaths/min, and
white blood cell count[12,000 cells/dL
or\4000 cells/dL) as a reference to aid the
clinician to determine if the patient was a can-
didate for dalbavancin therapy and determine if
the patient was medically ready for discharge.
Factors also evaluated for every patient were if
the patient was immunocompetent, hemody-
namically stable, afebrile, had a normal (base-
line) mental status, and willingness to consent
to this therapy option. The process involved a
multidisciplinary collaborative approach
including the physician, ID PharmD, case
manager, and infusion center patient assistance
coordinator [10]. Upon discharge, self-pay,
consenting patients received dalbavancin at the
health system’s on-site, outpatient infusion
center and the healthcare team applied for vial
replacement to assist with cost of therapy.
Patients were included if they were adult
inpatients admitted with self-pay insurance
status (i.e., uninsured) and an ABSSSI (Interna-
tional Classification of Disease, Tenth Revision
(ICD-10) codes L03.XXX, L02.XXX, T81.XXX
consistent with cellulitis, abscess, or postopera-
tive wound infection, respectively). Patients
were excluded if they were pregnant, did not
have dalbavancin vial replacement performed,
had infections caused exclusively by gram-neg-
ative bacteria or fungi, or ICD-10 codes consis-
tent with M86.XXX, M72.6, A48.0, E08.621/
E09.521/E10.621/E11.621/E13.621, represent-
ing osteomyelitis, necrotizing fasciitis, gan-
grene, or diabetic foot ulcer, respectively.
Background demographics including infectious
diagnosis, comorbid disease states, allergies,
hemodynamic status, renal and liver function,
and microbiology data were collected for study
subjects.
The primary outcome was total direct cost of
hospital stay, which was recorded as the total
direct cost per patient. The secondary outcomes
evaluated LOS, 30-day readmission rates,
adverse events (AE) during hospitalization, and
indirect costs of hospital stay. Direct costs con-
sisted of any monetary value attributed directly
to the treatment of infection with IV antibiotics
during the patients’ inpatient stay. This inclu-
ded costs associated with medical supplies, lab-
oratory, pharmacy, emergency department,
operating room, room stay, and salaries related
to medical personnel (e.g., nurses) directly
providing patient care. Indirect costs consisted
of monetary values that were not directly rela-
ted to that specific department (e.g., overhead
building costs or hospital administration cost).
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Costs are allocated monthly at the host facility
to each specific department after reports collect
the financial charges. Data was collected and
analyzed in MicrosoftOffice Excel. Categorical
data were assessed using chi-square or Fisher’s
exact test, as appropriate. Continuous data were
assessed using Student’s t test or Mann–Whit-
ney U, as appropriate. An alpha of 0.05 was
deemed statistically significant. A one-sided
Student’s t test was performed on the financial
data owing to previous aforementioned studies
suggesting the cost-savings effects of dalba-
vancin making an alpha of 0.025 statistically
significant.
RESULTS
A total of 397 self-pay inpatients with ABSSSI
were identified from February 3, 2016 to
August 5, 2019. After applying exclusion crite-
ria, 12 patients were discharged and received
dalbavancin with patient assistance and receipt
of vial replacement and were included in the
dalbavancin group and 263 patients received
normal course of care and were included in the
SOC group (Fig. 1). Patient demographics and
clinical characteristics are summarized in
Table 1. The mean age was around 42 years old
in both groups (p = 0.986) and patients were
typically male (171/275, 62.3%) with a higher
percentage of male patients in the dalbavancin
group. Additional common patient demo-
graphics included in this study were Caucasian
race (174/275, 63.3%) and diagnosis of cellulitis
(186/275, 67.6%). Hyperlipidemia (25.0% vs
5.0%, p = 0.026), cancer (16.7% vs 1.9%,
p = 0.033), and peripheral artery disease (PAD)
(8.3% vs 0, p = 0.044) were statistically higher
in the dalbavancin group compared to SOC. The
most common causative organism isolated in
the dalbavancin group was S. aureus (7/7, 100%)
compared to 58.6% in the SOC group
(p = 0.047). The majority of the positive cul-
tures were wound cultures in both the dalba-
vancin and SOC groups, 58.3% and 51.3%,
respectively. All patients (100%) in the dalba-
vancin group received vancomycin empirically
compared to 81.7% in the SOC group
(p = 0.135). Piperacillin/tazobactam, cefazolin,
and clindamycin IV were the next most com-
mon empiric therapy given.
The primary and secondary outcomes are
displayed in Table 2. The primary outcome
demonstrated that dalbavancin was associated
with a lower total direct cost per patient com-
pared to SOC ($2758 vs $4010, respectively,
p = 0.105). This resulted in dalbavancin shown
as a cost-saving option of $1252 per patient.
Focusing on secondary outcomes, the median
length of stay was similar in both groups
(4 days; p = 0.888) with similar readmission
rates in the dalbavancin vs SOC groups (1/12,
8.3% vs 19/263, 7.2%; p = 0.604, respectively).
There were no statistically significant differ-
ences for 30-day readmission rates, acute kidney
injury, or hospital acquired infections. Indirect
costs per patient were numerically lower in the
dalbavancin group ($2913 vs $3646; p = 0.162).
DISCUSSION
Overall this study demonstrated discharging
self-pay patients with a diagnosis of ABSSSI to
receive dalbavancin and patient assistance
through vial replacement to be an effective cost-
saving strategy. From 2005 to 2014 skin and
subcutaneous tissues infections in adults aged
18–44 years have been documented in the top
five reasons for hospital admission [21]. With
interventions in hospitals being focused on
patient outcomes that are clinically safe, effec-
tive, and cost conscientious, understanding the
financial impact of treatment options is
important in this common inpatient diagnosis
[22]. This study found dalbavancin to have no
difference in clinical outcomes or safety profile
based on no significant increase in LOS, 30-day
readmission rates, or adverse events while in the
hospital. In addition to dalbavancin being
shown as a clinically effective agent for ABSSSI
in self-pay patients, this study also highlights
the cost-savings aspect of choosing this therapy
which is discussed in more detail in paragraphs
below.
This study found that patients with ABSSSI
were consistent with patient characteristics in
previous studies analyzing the use of dalba-
vancin regarding age, gender, race, and
1046 Infect Dis Ther (2020) 9:1043–1053
infectious diagnosis [13–18]. Streifel et al. [13]
found that patients treated with dalbavancin in
their academic center had a mean age of
48.6 years with 22% of the infections being skin
and soft-tissue infections, only second behind
osteomyelitis. Morrisette et al. [14] found simi-
lar patients in their analysis of long-acting
lipoglycopeptides for ABSSSI. The majority of
the ABSSSI cases were cellulitis. This was con-
sistent with previous data showing cellulitis
and/or abscess making up 80% of the cases
while 20% had wound infections (e.g., post-
traumatic or postoperatively) [23]. There was no
difference found in antibiotic allergy status.
This is important to note as certain allergies
(e.g., penicillin) have been linked to increased
rates on antibiotic resistance, Clostridioides dif-
ficile, and increased use of broad-spectrum
antibiotics which could have influenced the
primary and secondary outcomes [24, 25]. A
numerically higher amount of IVDU in the
dalbavancin group were found (25% vs 13.7%,
p = 0.387). This was similar to the finding in the
study by Morrisette et al. [14] that also discov-
ered the high percentage of patients who are
IVDUs with methicillin-susceptible and methi-
cillin-resistant S. aureus infections are eligible
for dalbavancin. Outpatient parenteral antimi-
crobial therapy (OPAT), specifically long-acting
lipoglycopeptides, pose as a useful solution in
this patient population. There are many
advantages to this treatment option, especially
with dalbavancin. These include a reduced need
for long-term central lines which reduces
infection risk and substance abuse concerns,
increased compliance for patients with poor
adherence or difficult life situations (e.g.,
homelessness, incarceration, rural location)
Fig. 1 Patient enrollment breakdown
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Table 1 Patient clinical and microbiological characteristics
Variables Dalbavancin (n = 12) SOC (n = 263) p value
Age, years (mean ± SD) 41.75 ± 6.3 41.71 ± 11.6 0.986
Sex, male 12 (100) 159 (60.5) 0.006
Race
Caucasian 11 (91.7) 163 (62) 0.061
African American 1 (8.3) 92 (35) \ 0.001
Pacific Islander or unknown origin 0 (0) 8 (3) 1.000
ICD-10
Cellulitis (L03.XXX) 9 (75) 177 (67.3) 0.757
Abscess (L02.XXX) 3 (25) 79 (30) 0.002
Postop wound infections (T81.XXX) 0 (0) 7 (2.7) 1.000
Antibiotic allergies
Total 1 (8.3) 65 (24.7) 0.305
Penicillin 0 (0) 30 (11.4) 0.374
Sulfonamide 1 (8.3) 17 (6.5) 0.564
Clindamycin 0 (0) 5 (1.9) 1.000
Vancomycin 0 (0) 5 (1.9) 1.000
Other 0 (0) 8 (3.0) 1.000
Vitals
BMI, kg/m2 29.15 [26.9–38.7] 28.89 [23.5–35.4] 0.555
Initial BMI C 30 kg/m2 4 (33.3) 109 (41.4) 0.766
Maximum temperature in 24 h, F 98.85 [98.5–99.8] 98.9 [98.5–100.1] 0.761
Maximum temperature in 24 h, [ 100.4 F 2 (16.7) 65 (24.7) 0.736
C 2 (RR C 22, SBP B 100) 0 (0) 1 (0.38) 1.000
Maximum WBC in 24 h, cells/mm3 11.15 [9.4–15.3] 10.90 [8.7–15.1] 0.722
Maximum WBC in 24 h C 12 cells/mm3 4 (33.3) 114 (43.4) 0.564
Comorbidities
Diabetes 2 (16.7) 53 (20.2) 1.000
Hypertension 3 (25) 73 (27.8) 1.000
Hyperlipidemia 3 (25) 13 (4.9) 0.026
Cancer 2 (16.7) 5 (1.9) 0.033
Venous thromboembolism 2 (16.7) 10 (3.8) 0.090
Peripheral artery disease 1 (8.3) 0 (0) 0.044
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Table 1 continued
Variables Dalbavancin (n = 12) SOC (n = 263) p value
Chronic kidney disease 0 (0) 4 (1.5) 1.000
Hepatitis 1 (8.3) 13 (4.9) 0.473
Cirrhosis 0 (0) 3 (1.1) 1.000
ABSSSI history documented 4 (33.3) 59 (22.4) 0.480
History of Clostridioides difficile 1 (8.3) 3 (1.1) 0.164
IVDU 3 (25) 36 (13.7) 0.387
Recreation drug abuse (non-IV) 3 (25) 59 (22.4) 0.736
Smoker 8 (66.7) 144 (54.8) 0.557
ID consult 10 (37) 126 (47.9) 0.019
Microbiological data
Cultures obtained 12 (100) 234 (89) 0.622
Wound culture 8 (30.8) 148 (29.7) 0.562
Abscess culture 4 (15.4) 105 (21.1) 0.769
Blood culture 10 (38.5) 189 (38) 0.521
Urine culture 4 (15.38) 56 (11.24) 0.301
Positive culture 7 (58.3) 128 (54.7) 0.566
S. aureus infection 7 (100) 75 (58.6) 0.047
MRSA 4 (57.1) 39 (52) 0.100
MSSA 3 (42.9) 35 (46.7) 0.221
Blood culture 0 (0) 21 (9) 0.608
Wound culture 7 (58.3) 120 (51.3) 0.556
Urine culture 0 (0) 11 (4.7) 1.000
Inpatient antibiotics
Vancomycin 12 (100) 215 (81.7) 0.135
Piperacillin/tazobactam 6 (50) 162 (61.6) 0.547
Meropenem 0 (0) 1 (0.4) 1.000
Cefazolin 4 (33.3) 41 (15.6) 0.114
Clindamycin (IV/PO) 3 (25) 143 (54.4) 0.073
Other 3 (25) 102 (38.8) 0.545
Data are presented as n (%) or median [IQR] unless otherwise indicated
BMI body mass index, RR respiratory rate, SBP systolic blood pressure, IVDU intravenous drug users, ID infectious
diseases, MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus, PO oral
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with a one-time dose, and discharge assistance
when oral antibiotics may not be adequate
treatment [15].
Interestingly, there were a high amount of
infectious diseases (ID) consults in this popula-
tion, with a higher percentage in the SOC group
(37% vs 48%). This could be attributed to the
underlying difficult transitions of care decisions
with a self-pay patient population [26]. All of
the patients discharged to receive dalbavancin
in this study were empirically started on van-
comycin at admission. This could be explained
as vancomycin is one of the targeted antimi-
crobial therapies reviewed by the ID PharmD on
a daily basis and the difficulties in identifying
possible dalbavancin candidates in a reasonable
timeframe. The increased risk of side effects and
lack of alternate treatment options lend to the
ID PharmD being able to determine potential
dalbavancin candidates and assist with transi-
tions of care [27]. The impact of the ID PharmD
has been shown in the previous study, as they
are able to assist with clinical knowledge skills
to aid in selecting, counseling, and effectively
treating this patient population with dalba-
vancin [10].
Results showed discharging to receive dal-
bavancin for ABSSSI to be a cost-saving option
of $1252 per patient. Previous studies have
shown both cost and LOS reduction benefits
with dalbavancin. Streifel et al. [13] found that
analyzing 27 patients who received dalbavancin
found an avoidance of 617 hospital days which
resulted in a mean cost savings per patient of
$40,414; however, that study did include non-
ABSSSI cases. An additional study in Germany
demonstrated the cost-savings effect of dalba-
vancin in MRSA ABSSSI by reducing LOS by
6.45 days with a cost savings of $3099.69
(2865 €) [16]. The previous study at our insti-
tution was associated with decreased cost and
length of stay [10]. The impact of vial replace-
ment was shown to mirror previous data of
dalbavancin as a cost-effective option in the
self-pay population. To our knowledge, there
are no current data to compare the financial
results to self-pay patients. For those with third-
party payers, dalbavancin has been shown to
save $1442 to $4803 per complicated skin and
soft-tissue infection (cSSTI) case with a safe
adverse event profile [28].
In an economic evaluation of dalbavancin in
three European countries, dalbavancin was
found to reduce length of stay for patients with
ABSSSI by 3.3 days per patient with no addi-
tional cost towards the health system [17].
Additionally, McCarthy et al. [18] found a
reduction in length of stay (3.2 days vs 4.8 days,
p = 0.003) which was attributed to an increase
in productivity for the staff. While this study
did not result in a significant decrease in length
of stay, there were two confounding factors that
could have contributed to this. One patient in
the dalbavancin group had a LOS of 11 days.
There was an attempt to adjust for this by pre-
senting the data as median days. Additionally,
for ABSSSI there was a high percentage in the






















0 (0) 33 (12.6) 0.371
Hospital acquired
infection
0 (0) 2 (0.8) 1.000
Documented
infusion reaction
0 (0) 4 (1.5) 1.000
Median length of
stay, days
4 [2.8–4.3] 4 [2–6] 0.888
30-day
readmission rate
1 (8.3%) 19 (7.2%) 0.604
Data are presented as n (%) or median [IQR]
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standard of care group of ID consults (47.9%),
which could have contributed to a shorter
length of stay. The adverse event profile was
similar in this study between the two groups.
This was important since previous literature has
shown MRSA ABSSSI treated with vancomycin
has an increased risk for acute kidney injury
(AKI) in patients with no medical insurance (OR
3.451, 95% CI 1.131–9.090) [27]. The rates of
AKI in both treatment groups were similar
despite 50% of MRSA infections in both groups.
Several limitations are present within this
study. First, the low number of patients enrolled
in the dalbavancin arm (n = 12) makes it diffi-
cult to determine definitive conclusions on
safety and efficacy. Similarly, the retrospective
nature of this design limited the ability to
control factors, such as patient assistance and
vial replacement receipt. The 15 patients that
did not have vial replacement performed iden-
tify a performance improvement for our insti-
tution but a limitation of this study.
Additionally, these patients were not random-
ized. This led to certain comorbidity and infec-
tion etiology discrepancies that could have
influenced clinical parameters outside of costs.
During the screening process for patients, it was
found that some patients had a documented
abscess infection without a matching ICD-10
code. This potential human error could have
resulted in fewer patients being included in the
two groups and lower numbers in the abscess
groups. Some patients who met inclusion cri-
teria might not have been candidates for dal-
bavancin therapy. This is because only primary
diagnosis codes for inclusion or exclusion cri-
teria were used. Secondary codes could have
influenced LOS or prohibited use of dalba-
vancin therapy. Access to the financial data was
limited because some accounts were frozen for
financial reimbursement investigation or
deemed charity. Indirect costs were limited to
data on current inpatient stay and do not reflect
any outpatient costs (i.e., outpatient antibiotic
prescriptions) associated with care beyond dal-
bavancin patients receiving infusion.
CONCLUSION
These findings suggest that discharging self-pay
patients diagnosed with an ABSSSI to receive
dalbavancin at an infusion center is less
expensive than the inpatient standard of care
for treating self-pay patients with ABSSSI.
Although this study did not show a decrease in
LOS or 30-day readmission rate similar to pre-
vious studies, it did not show an increase.
Future analysis could include a prospective
analysis consisting of a larger number of self-
pay dalbavancin patients ensuring vial replace-
ment is performed. These findings help provide
a guide for community hospitals for selecting
and making financially sound decisions for
treating patients with ABSSSI with dalbavancin.
ACKNOWLEDGEMENTS
Funding. No funding or sponsorship was
received for this study or publication of this
article.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Prior Presentation. Preliminary data was
presented on April 28, 2020 at the virtual
Georgia Society of Health-System Pharmacists
Spring meeting.
Disclosures. Christopher M. Bland is on the
Speaker’s Bureau for Merck and Tetraphase, on
the Advisory Board for Merck and Paratek, and
has received grant funding from ALK-Abello.
Bruce M. Jones is on the Speaker’s Bureau for
Allergan, Tetraphase, and Paratek and has
received grant funding from and participates in
consulting for ALK-Abello. E. Yancey Murray,
Derek A. Gaul, and Jamie L. Wagner have no
conflicts of interest. Adam G. Pizzuti is now
affiliated with Prisma Health Midlands,
Columbia, SC, USA.
Infect Dis Ther (2020) 9:1043–1053 1051
Compliance with Ethics Guidelines. This
study received IRB-approval from St. Joseph’s/
Candler Health system. In addition, this study
adheres to the declaration of Helsinki of 1964
and its later amendments.
Data Availability. All datasets are made
available in this published article and are
available from the corresponding author on
reasonable request.
Open Access. This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License, which permits
any non-commercial use, sharing, adaptation,
distribution and reproduction in any medium
or format, as long as you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons licence, and
indicate if changes were made. The images or
other third party material in this article are
included in the article’s Creative Commons
licence, unless indicated otherwise in a credit
line to the material. If material is not included
in the article’s Creative Commons licence and
your intended use is not permitted by statutory
regulation or exceeds the permitted use, you
will need to obtain permission directly from the




1. Food and Drug Administration. Guidance for
industry acute bacterial skin and skin structure
infections: developing drugs for treatment. FDA.
2013. https://www.fda.gov/media/71052/
download. Accessed 30 Jan 2020.
2. Stevens DL, Bisno AL, Chambers HF, et al. Practice
guidelines for the diagnosis and management of
skin and soft tissue infections update by the Infec-
tious Diseases Society of America. Clin Infect Dis.
2014;59:e10–52.
3. Bookstaver PB, Jenkins TC, Stenehjem E, et al.
Impact of outpatient vs inpatient ABSSSI treatment
on outcomes: a retrospective observational analysis
of medical charts across US Emergency Depart-
ments. Open Forum Infect Dis. 2018;5(7):ofy109.
4. Bork JT, Heil EL, Berry S, et al. Dalbavancin use in
vulnerable patients receiving outpatient parenteral
antibiotic therapy for invasive gram-positive infec-
tions. Infect Dis Ther. 2019;8:171–84.
5. Kaye KS, Patel DA, Stephens JM, Khachatryan A,
Patel A, Johnson K. Rising United States hospital
admissions for acute bacterial skin and skin struc-
ture infections: recent trends and economic impact.
PLoS One. 2015;10(11):e0143276. https://doi.org/
10.1371/journal.pone.0143276.
6. Nagamine M, Stocks C, Merrill C. Trends in unin-
sured hospital stays, 1998–2007: Statistical Brief
#88. 2010. In: Healthcare cost and utilization pro-
ject (HCUP) statistical briefs [Internet]. Rockville
(MD): Agency for Healthcare Research and Quality
(US); 2006.
7. Cohen RA, Terlizzi EP, Martinez ME. Health insur-
ance coverage: early release of estimates from the
National Health Interview Survey, 2018. Hyattsville
(MD): National Center for Health Statistics. 2019.
https://www.cdc.gov/nchs/data/nhis/earlyrelease/
insur201905.pdf. Accessed 31 Jan 2020.
8. American Hospital Association. Uncompensated
hospital care cost fact sheet. 2019. https://www.
aha.org/system/files/2019-01/uncompensated-care-
fact-sheet-jan-2019.pdf. Accessed 12 Sep 2019.
9. Nagamine M, Stocks C, Merrill C. Trends in unin-
sured hospital stays, 1998–2007: Statistical Brief#
88. 2006. https://www.ncbi.nlm.nih.gov/books/
NBK53604/. Accessed 30 Jan 2020.
10. Jones BM, Hersey R, Taylor C, Bland CM. Evalua-
tion of dalbavancin on length of stay in acute
bacterial skin and skin structure infections. J Am
Coll Clin Pharm. 2019. https://doi.org/10.1002/
jac5.1085.
11. Dalbavancin [package insert]. Parsippany, NJ: Dur-
ata Therapeutics, Inc.; 2014. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2014/021883s000lbl.pdf. Accessed 20 Sept
2019.
12. Dunne MW, Puttagunta S, Giordano P, Krievins D,
Zelasky M, Baldassarre J. A randomized clinical trial
of single-dose versus weekly dalbavancin for treat-
ment of acute bacterial skin and skin structure
infection. Clin Infect Dis. 2016;625:545–551.
13. Streifel AC, Sikkab MK, Bowena CD, Lewis JS II.
Dalbavancin use in an academic medical centre and
associated cost savings. Int J Antimicrobial Agents.
2019;54:652–654.
14. Morrisette T, Miller MA, Montague BT, Barber GR,
McQueen RB, Krsak M. On- and off-label utilization
of dalbavancin and oritavancin for Gram-positive
1052 Infect Dis Ther (2020) 9:1043–1053
infections. J Antimicrob Chemother. 2019;74(8):
2405–16.
15. Krsak M, Morrisette T, Miller M, et al. Advantages of
outpatient treatment with long-acting lipogly-
copeptides for serious gram-positive infections: a
review. Pharmacotherapy. 2020. https://doi.org/10.
1002/phar.2389.
16. Wilke M, Worf K, Preisendörfer B, Heinlein W, Kast
T, Bodmann KF. Potential savings through single-
dose intravenous Dalbavancin in long-term MRSA
infection treatment—a health economic analysis
using German DRG data. GMS Infect Dis.
2019;2019:7.
17. Marcellusi A, Viti R, Sciattella P, et al. Economic
evaluation of the treatment of acute bacterial skin
and skin structure infections (ABSSSIs) from the
national payer perspective: introduction of a new
treatment to the patient journey. A simulation of
three European countries. Expert Rev Pharma-
coecon Outcomes Res. 2019;19(5):581–599.
18. McCarthy MW, Keyloun KR, Gillard P, et al. Dal-
bavancin reduces hospital stay and improves pro-
ductivity for patients with acute bacterial skin and
skin structure infections: the ENHANCE trial. Infect
Dis Ther. 2020;9(1):53–67.
19. Dalbavancin Website. Coding, coverage, and reim-
bursement. 2019. https://www.dalvance.com/
coding-and-reimbursement. Accessed 30 Jan 2020.
20. Dalbavancin. Needy meds medication assistance.
2020. https://www.needymeds.org/generic-drug/
name/dalbavancin. Accessed 25 Mar 2020.
21. McDermott, KW, Anne E, Ruirui S. Trends in hos-
pital inpatient stays in the United States,
2005–2014. HCUP Stat Brief. 2017;2017:225.
https://www.hcup-us.ahrq.gov/reports/statbriefs/
sb225-Inpatient-US-Stays-Trends.pdf.
22. Grol R, Grimshaw J. From best evidence to best
practice: effective implementation of change in
patients’ care. Lancet. 2003;362(9391):1225–300.
23. Pulido-Cejudo A, Guzmán-Gutierrez M, Jalife-
Montaño A, et al. Management of acute bacterial
skin and skin structure infections with a focus on
patients at high risk of treatment failure. Thera-
peutic Adv Infect Dis. 2017;4(5):143–161.
24. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Eval-
uation and management of penicillin allergy: a
review. JAMA. 2019;321(2):188–99.
25. Jones BM, Avramovski N, Concepcion AM, Crosby
J, Bland CM. Clinical and economic outcomes of
penicillin skin testing as an antimicrobial steward-
ship initiative in a community health system. Open
Forum Infect Dis. 2019;6(4):ofz109.
26. Bhavan KP, Brown LS, Haley RW. Self-administered
outpatient antimicrobial infusion by uninsured
patients discharged from a safety-net hospital: a
propensity-score-balanced retrospective cohort
study. PLoS Med. 2015;12(12):e1001922. https://
doi.org/10.1371/journal.pmed.1001922.
27. Jorgensen SCJ, Murray KP, Lagnf AM, et al. A mul-
ticenter evaluation of vancomycin-associated acute
kidney injury in hospitalized patients with acute
bacterial skin and skin structure infections. Infect
Dis Ther. 2020;9:89–106.
28. Agarwal R, Bartsch SM, Kelly BJ, et al. Newer gly-
copeptide antibiotics for treatment of complicated
skin and soft tissue infections: systematic review,
network meta-analysis and cost analysis. Clin
Microbiol Infect. 2018;24(4):361–368.
Infect Dis Ther (2020) 9:1043–1053 1053
